Demystifying the management of hypertriglyceridaemia

Nature Reviews Cardiology

Volumn 10, Issue 11, 2013, Pages 648-661

  Watts, Gerald F ^a   Ooi, Esther M M ^a   Chan, Dick C ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B100; APOLIPOPROTEIN C3; APOLIPOPROTEIN C3 INHIBITOR; ASPARAGINASE; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; CYCLOSPORIN; DIACYLGLYCEROL ACYLTRANSFERASE; DIACYLGLYCEROL ACYLTRANSFERASE INHIBITOR; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; LIPOPROTEIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; NICOTINIC ACID; PROTEIN INHIBITOR; RAPAMYCIN; RETINOIC ACID DERIVATIVE; TAMOXIFEN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; TRIGLYCERIDE RICH LIPOPROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATHEROGENESIS; ATHEROGENIC DYSLIPIDEMIA; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CALORIC RESTRICTION; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; DIETARY INTAKE; DISEASE ASSOCIATION; DRUG MECHANISM; EXERCISE; FATTY LIVER; GENE REPLACEMENT THERAPY; GENETIC VARIABILITY; HEREDITY; HOMOZYGOSITY; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID STORAGE; LIPOPROTEIN METABOLISM; LOSS OF FUNCTION MUTATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WEIGHT REDUCTION;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; GENETIC PREDISPOSITION TO DISEASE; GENETIC THERAPY; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; RISK FACTORS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84886727920     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2013.140     Document Type: Review

References (180)

1. Friedewald, W. T., Levy, R. I. & Fredrickson, D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499-502 (1972).
2. Tiyyagura, S. & Smith, D. Standard lipid profile. Clin. Lab. Med. 26, 707-732 (2006).
3. Baigent, C. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278 (2005).
4. Mihaylova, B. et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380, 581-590 (2012).
5. Reiner, Z. et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 32, 1769-1818 (2011).
6. Goldberg, I. J., Eckel, R. H. & McPherson, R. Triglycerides and heart disease: still a hypothesis? Arterioscler. Thromb. Vasc. Biol. 31, 1716-1725 (2011).
7. Durrington, P. Triglycerides are more important in atherosclerosis than epidemiology has suggested. Atherosclerosis 141 (Suppl. 1), S57-S62 (1998).
8. Phillips, A. N. & Smith, G. D. How independent are "independent" effects? Relative risk estimation when correlated exposures are measured imprecisely. J. Clin. Epidemiol. 44, 1223-1231 (1991).
9. Miller, M. et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 123, 2292-2333 (2011).
10. Chapman, M. J. et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. 32, 1345-1361 (2011).
11. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 106, 3143-3421 (2002).
12. Berglund, L. et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 97, 2969-2989 (2012).
13. Anderson, T. J. et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can. J. Cardiol. 29, 151-167 (2013).
14. Teramoto, T. et al. Executive summary of Japan Atherosclerosis Society (JAS). Guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan-2012 version. J. Atheroscler. Thromb. 20, 517-523 (2013).
15. Shimano, H. et al. Proposed guidelines for hypertriglyceridemia in Japan with non-HDL cholesterol as the second target. J. Atheroscler. Thromb. 15, 116-121 (2008).
16. Gotoda, T. et al. Diagnosis and management of type I and type V hyperlipoproteinemia. J. Atheroscler. Thromb. 19, 1-12 (2012).
17. Leiter, L. A. et al. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet. Med. 28, 1343-1351 (2011).
18. Brunzell, J. D. Clinical practice. Hypertriglyceridemia. N. Engl. J. Med. 357, 1009-1017 (2007).
19. Johansen, C. T. & Hegele, R. A. The complex genetic basis of plasma triglycerides. Curr. Atheroscler. Rep. 14, 227-234 (2012).
20. Johansen, C. T., Kathiresan, S. & Hegele, R. A. Genetic determinants of plasma triglycerides. J. Lipid Res. 52, 189-206 (2011).
21. Surendran, R. P. et al. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J. Intern. Med. 272, 185-196 (2012).
22. Johansen, C. T. et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat. Genet. 42, 684-687 (2010).
23. Durrington, P. Dyslipidaemia. Lancet 362, 717-731 (2003).
24. Brouwers, M. C., van Greevenbroek, M. M., Stehouwer, C. D., de Graaf, J. & Stalenhoef, A. F. The genetics of familial combined hyperlipidaemia. Nat. Rev. Endocrinol. 8, 352-362 (2012).
25. Hopkins, P. N. et al. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation 108, 519-523 (2003).
26. Voors-Pette, C. & de Bruin, T. W. Excess coronary heart disease in familial combined hyperlipidemia, in relation to genetic factors and central obesity. Atherosclerosis 157, 481-489 (2001).
27. Kissebah, A. H., Alfarsi, S. & Evans, D. J. Low density lipoprotein metabolism in familial combined hyperlipidemia. Mechanism of the multiple lipoprotein phenotypic expression. Arteriosclerosis 4, 614-624 (1984).
28. Veerkamp, M. J., de Graaf, J., Hendriks, J. C., Demacker, P. N. & Stalenhoef, A. F. Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study. Circulation 109, 2980-2985 (2004).
29. Dionne, C. et al. Genetic epidemiology of lipoprotein lipase deficiency in Saguenay-Lac-St-Jean (Québec, Canada). Ann. Genet. 35, 89-92 (1992).
30. Blom, D. J. & Marais, A. D. Severe hypertriglyceridemia in a patient with lupus. Am. J. Med. 118, 443-444 (2005)
31. Leaf, D. A. Chylomicronemia and the chylomicronemia syndrome: a practical approach to management. Am. J. Med. 121, 10-12 (2008).
32. Chan, D. C. & Watts, G. F. Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. Expert Opin. Pharmacother. 12, 13-30 (2011).
33. Taskinen, M. R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46, 733-749 (2003).
34. Davidson, M. H. et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J. Clin. Lipidol. 5, 338-367 (2011).
35. Arner, P. et al. Dynamics of human adipose lipid turnover in health and metabolic disease. Nature 478, 110-113 (2011).
36. Xiao, C., Hsieh, J., Adeli, K. & Lewis, G. F. Gut-liver interaction in triglyceride-rich lipoprotein metabolism. Am. J. Physiol. Endocrinol. Metab. 301, E429-E446 (2011).
37. Adiels, M., Olofsson, S. O., Taskinen, M. R. & Borén, J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28, 1225-1236 (2008).
38. Angulo, P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346, 1221-1231 (2002).
39. Britton, K. A. & Fox, C. S. Ectopic fat depots and cardiovascular disease. Circulation 124, e837-e841 (2011).
40. Borén, J., Taskinen, M. R. & Olofsson, S. O. & Levin, M. Ectopic lipid storage and insulin resistance: a harmful relationship. J. Intern. Med. 274, 25-40 (2013).
41. Granér, M. et al. Cardiac steatosis associates with visceral obesity in nondiabetic obese men. J. Clin. Endocrinol. Metab. 98, 1189-1197 (2013).
42. Bartelt, A. et al. Brown adipose tissue activity controls triglyceride clearance. Nat. Med. 17, 200-205 (2011).
43. Ooi, E. M., Barrett, P. H., Chan, D. C. & Watts, G. F. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin. Sci. 114, 611-624 (2008).
44. Taskinen, M. R. et al. Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler. Thromb. Vasc. Biol. 31, 2144-2150 (2011).
45. Rashid, S., Watanabe, T., Sakaue, T. & Lewis, G. F. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin. Biochem. 36, 421-429 (2003).
46. Arsenault, B. J. et al. HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Atherosclerosis 206, 276-281 (2009).
47. Di Angelantonio, E. et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302, 1993-2000 (2009).
48. Johansen, C. T. & Hegele, R. A. Using Mendelian randomization to determine causative factors in cardiovascular disease. J. Intern. Med. 273, 44-47 (2013).
49. Jørgensen, A. B. et al. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur. Heart J. 34, 1826-1833 (2013).
50. Sarwar, N. et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 375, 1634-1639 (2010).
51. Miller, M. et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J. Am. Coll. Cardiol. 51, 724-730 (2008).
52. Faergeman, O. et al. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am. J. Cardiol. 104, 459-463 (2009).
53. Boekholdt, S. M. et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 307, 1302-1309 (2012).
54. Zilversmit, D. B. Atherogenesis: a postprandial phenomenon. Circulation 60, 473-485 (1979).
55. Nordestgaard, B. G. & Nielsen, L. B. Atherosclerosis and arterial influx of lipoproteins. Curr. Opin. Lipidol. 5, 252-257 (1994).
56. Tabas, I., Williams, K. J. & Borén, J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 116, 1832-1844 (2007).
57. Goldstein, J. L., Ho, Y. K., Brown, M. S., Innerarity, T. L. & Mahley, R. W. Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolemic canine beta-very low density lipoproteins. J. Biol. Chem. 255, 1839-1848 (1980).
58. Zheng, X. Y. & Liu, L. Remnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthase. J. Lipid Res. 48, 1673-1680 (2007).
59. Kohler, H. P. & Grant, P. J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N. Engl. J. Med. 342, 1792-1801 (2000).
60. Moyer, M. P. et al. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler. Thromb. Vasc. Biol. 18, 458-465 (1998).
61. Alipour, A. et al. Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler. Thromb. Vasc. Biol. 28, 792-797 (2008).
62. Wang, L. et al. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J. Lipid Res. 50, 204-213 (2009).
63. Kolovou, G. D. et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr. Vasc. Pharmacol. 9, 258-270 (2011).
64. Nordestgaard, B. G., Benn, M., Schnohr, P. & Tybjaerg-Hansen, A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298, 299-308 (2007).
65. International Atherosclerosis Society. IAS Position Paper: Global Recommendations for the Management of Dyslipidemia [online], http://www.athero.org/IASPositionPaper.asp (2013).
66. Jiang, R. et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 27, 1991-1997 (2004).
67. Ridker, P. M., Rifai, N., Cook, N. R., Bradwin, G. & Buring, J. E. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 294, 326-333 (2005).
68. Lu, W. et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the Strong Heart Study. Diabetes Care 26, 16-23 (2003).
69. Cui, Y. et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch. Intern. Med. 161, 1413-1419 (2001).
70. Walldius, G. et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358, 2026-2033 (2001).
71. Cole, T. G. et al. Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices. Clin. Chem. 59, 752-770 (2013).
72. Sniderman, A., Couture, P. & de Graaf, J. Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. Nat. Rev. Endocrinol. 6, 335-346 (2010).
73. Sniderman, A. D., Williams, K., McQueen, M. J. & Furberg, C. D. When is equal not equal? J. Clin. Lipidol. 4, 83-88 (2010).
74. van Gaal, L. F., Wauters, M. A. & De Leeuw, I. H. The beneficial effects of modest weight loss on cardiovascular risk factors. Int. J. Obes. Relat. Metab. Disord. 21 (Suppl. 1), S5-S9 (1997).
75. Dattilo, A. M. & Kris-Etherton, P. M. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am. J. Clin. Nutr. 56, 320-328 (1992).
76. Sacks, F. M. et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N. Engl. J. Med. 360, 859-873 (2009).
77. Shai, I. et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N. Engl. J. Med. 359, 229-241 (2008).
78. Mensink, R. P., Zock, P. L., Kester, A. D. & Katan, M. B. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am. J. Clin. Nutr. 77, 1146-1155 (2003).
79. Schaefe, E. J. Lipoproteins, nutrition, and heart disease. Am. J. Clin. Nutr. 75, 191-212 (2002).
80. Appel, L. J. et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA 294, 2455-2464 (2005).
81. Livesey, G. & Taylor, R. Fructose consumption and consequences for glycation, plasma triacylglycerol, and body weight: meta-analyses and meta-regression models of intervention studies. Am. J. Clin. Nutr. 88, 1419-1437 (2008).
82. Anderson, J. W., Randles, K. M., Kendall, C. W. & Jenkins, D. J. Carbohydrate and fiber recommendations for individuals with diabetes: a quantitative assessment and meta-analysis of the evidence. J. Am. Coll. Nutr. 23, 5-17 (2004).
83. Rumawas, M. E., Meigs, J. B., Dwyer, J. T., McKeown, N. M. & Jacques, P. F. Mediterranean-style dietary pattern, reduced risk of metabolic syndrome traits, and incidence in the Framingham Offspring Cohort. Am. J. Clin. Nutr. 90, 1608-1614 (2009).
84. Estruch, R. et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N. Engl. J. Med. 368, 1279-1290 (2013).
85. Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393-403 (2002).
86. Wing, R. R. et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 34, 1481-1486 (2011).
87. Braith, R. W. & Stewart, K. J. Resistance exercise training: its role in the prevention of cardiovascular disease. Circulation 113, 2642-2650 (2006).
88. Hannuksela, M. L., Liisanantti, M. K. & Savolainen, M. J. Effect of alcohol on lipids and lipoproteins in relation to atherosclerosis. Crit. Rev. Clin. Lab. Sci. 39, 225-283 (2002).
89. Wing, R. R. et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N. Engl. J. Med. 369, 145-154 (2013).
90. Stein, E. A., Lane, M. & Laskarzewski, P. Comparison of statins in hypertriglyceridemia. Am. J. Cardiol. 81, 66B-69B (1998)
91. Ginsberg, H. N. Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J. Clin. Endocrinol. Metab. 91, 383-392 (2006).
92. Deedwania, P. C. et al. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am. J. Cardiol. 95, 360-366 (2005).
93. Kearney, P. M. et al. Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371, 117-125 (2008).
94. Robinson, J. G., Wang, S., Smith, B. J. & Jacobson, T. A. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J. Am. Coll. Cardiol. 53, 316-322 (2009).
95. Athyros, V. G. et al. Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients. Lipids 42, 999-1009 (2007).
96. Puri, R. et al. Factors underlying regression of coronary atheroma with potent statin therapy. Eur. Heart J. 34, 1818-1825 (2013).
97. Watts, G. F. & Karpe, F. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Heart 97, 350-356 (2011).
98. Ginsberg, H. et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563-1574 (2010).
99. Staels, B. et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98, 2088-2093 (1998).
100. Chapman, M. J., Redfern, J. S., McGovern, M. E. & Giral, P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol. Ther. 126, 314-345 (2010).
101. Watts, G. F. et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 52, 803-811 (2003).
102. Jun, M. et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375, 1875-1884 (2010).
103. Frick, M. H. et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317, 1237-1245 (1987).
104. Manninen, V. et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85, 37-45 (1992).
105. Rubins, H. B. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341, 410-418 (1999).
106. Rubin, H. B. et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch. Intern. Med. 162, 2597-2604 (2002).
107. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) Study. Circulation 102, 21-27 (2000).
108. Keech, A. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9, 795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849-1861 (2005).
109. Scott, R. et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9, 795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 32, 493-498 (2009).
110. Sacks, F. M., Carey, V. J. & Fruchart, J. C. Combination lipid therapy in type 2 diabetes. N. Engl. J. Med. 363, 692-695 (2010).
111. Keech, A. C. et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370, 1687-1697 (2007).
112. Chew, E. Y. et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N. Engl. J. Med. 363, 233-244 (2010).
113. Jun, M. et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis. J. Am. Coll. Cardiol. 60, 2061-2071 (2012).
114. Canner, P. L. et al. Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. 8, 1245-1255 (1986).
115. Brown, B. G. et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345, 1583-1592 (2001).
116. Taylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K. & Grace, K. A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110, 3512-3517 (2004).
117. Taylor, A. J. et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med. 361, 2113-2122 (2009).
118. Boden, W. E. et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365, 2255-2267 (2011).
119. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25, 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 34, 1279-1291 (2013).
120. Guyton, J. R. et al. Relationship of lipoproteins to cardiovascular events in the atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides and impact on global health outcomes (AIM-HIGH) trial. J. Am. Coll. Cardiol. http://dx.doi.org/10.1016/j.jacc.2013.07.023.
121. Carlson L. A. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med. 258, 94-114 (2005).
122. Saravanan, P., Davidson, N. C., Schmidt, E. B. & Calder, P. C. Cardiovascular effects of marine omega-3 fatty acids. Lancet 376, 540-550 (2010).
123. Bosch J. et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N. Engl. J. Med. 367, 309-318 (2012).
124. Roncaglioni, M. C. et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N. Engl. J. Med. 368, 1800-1808 (2013).
125. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354, 447-455 (1999).
126. Davidson, M. H. et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin. Ther. 29, 1354-1367 (2007).
127. Ballantyne, C. M. et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am. J. Cardiol. 110, 984-992 (2012).
128. Rader, D. J. et al. Apolipoprotein C-III is significantly reduced by prescription omega-3 free fatty acids (Epanova) in patients with severe hypertriglyceridemia and changes correlate with increases in LDL-C: a sub-analysis of the EVOLVE trial (abstract). Circulation 126, A19030 (2012).
129. US National Library of Medicine. ClinicalTrials.gov [online] http://clinicaltrials.gov/show/NCT01492361 (2012).
130. Yokoyama, M. et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369, 1090-1098 (2007).
131. Brasky, T. M. et al. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J. Natl Cancer Inst. http://dx.doi.org/10.1093/jnci/ djt174.
132. Pandor, A. et al. Ezetimibe monotherapy for cholesterol lowering in 2, 722 people: systematic review and meta-analysis of randomized controlled trials. J. Intern. Med. 265, 568-580 (2009).
133. Kikuchi, K. et al. Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia. J. Atheroscler. Thromb. 19, 1093-1101 (2012).
134. Nakamura, T. et al. A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. J. Cardiol. 60, 12-17 (2012).
135. Chan, D. C., Watts, G. F., Gan, S. K., Ooi, E. M. & Barrett, P. H. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 33, 1134-1139 (2010).
136. Tremblay, A. J., Lamarche, B., Hogue, J. C. & Couture, P. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. J. Lipid Res. 50, 1463-1471 (2009).
137. Goldberg, R. B. et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin. Proc. 81, 1579-1588 (2006).
138. Rossebø, A. et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. 359, 1343-1356 (2008).
139. Fleg, J. et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J. Am. Coll. Cardiol. 52, 2198-2205 (2008).
140. Kastelein, J. J. et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358, 1431-1443 (2008).
141. Peto, R. et al. Analyses of cancer data from three ezetimibe trials. N. Engl. J. Med. 359, 1357-1366 (2008).
142. Baigent, C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377, 2181-2192 (2011).
143. Califf, R. M. et al. An update on the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am. Heart J. 159, 705-709 (2010).
144. Kim, W. & Egan, J. M. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol. Rev. 60, 470-512 (2008).
145. Watts, G. F. & Chan, D. C. Novel insights into the regulation of postprandial lipemia by glucagon-like peptides: significance for diabetes. Diabetes 62, 336-338 (2013).
146. Cobble, M. E. & Frederich, R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc. Diabetol. 11, 6 (2012).
147. Gaudet, D. et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 20, 361-369 (2013).
148. Wierzbicki A. S. & Viljoen, A. Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency. Expert Opin. Biol. Ther. 13, 7-10 (2013).
149. Gaudet, D. et al. Medical resource use and costs associated with chylomicronemia. J. Med. Econ. 16, 657-666 (2013).
150. Cariou, B. et al. Dual peroxisome proliferator-activated receptor α/{delta} agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care http://dx.doi.org/10. 2337/dc12-2012.
151. Cariou, B., Zaïr, Y., Staels, B. & Bruckert, E. Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 34, 2008-2014 (2011).
152. Staels, B. et al. Hepato-protective effects of the dual PPARα/δ agonist GFT505 in rodent models of NAFLD/NASH. Hepatology http://dx.doi.org/10.1002/hep.26461.
153. Henry, R. R. et al. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 374, 126-135 (2009).
154. Roche. Media Release: Roche halts investigation of aleglitazar following regular safety review of phase III trial [online], http://www.roche.com/media/ mediareleases/med-cor-2013-07-10.htm (2013).
155. Barter, P. J. & Rye, K. A. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J. Lipid Res. 53, 1755-1766 (2012).
156. Fayad, Z. A. et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 378, 1547-1559 (2011).
157. Schwartz, G. G. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089-2099 (2012).
158. Meyers, C. et al. The DGAT1 inhibitor LCQ908 decreases triglyceride levels in patients with the familial chylomicronemia syndrome. J. Clin. Lipidol. 6, 266-267 (2012).
159. Denison, H. et al. Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study. Diabetes Obes. Metab. 15, 136-143 (2013).
160. Cuchel, M. et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 381, 40-46 (2013).
161. Raal, F. J. et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375, 998-1006 (2010).
162. Graham, M. J. et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ. Res. 112, 1479-1490 (2013).
163. rd Scientific Sessions (2013).
164. Lambert, G., Sjouke, B., Choque, B., Kastelein, J. J. & Hovingh, G. K. The PCSK9 decade. J. Lipid Res. 53, 2515-2524 (2012).
165. Lee, E. C. et al. Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL). J. Biol. Chem. 284, 13735-13745 (2009).
166. Brunzell, J. D. et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 31, 811-822 (2008).
167. Rubiés-Prat, J. et al. Calculated low-density lipoprotein cholesterol should not be used for management of lipoprotein abnormalities in patients with diabetes mellitus. Diabetes Care 16, 1081-1086 (1993).
168. Wierzbicki, A. S. The fats of life in diabetes. Br. J. Diabetes Vasc. Dis. 12, 216-220 (2012).
169. Sniderman, A. D. Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice. J. Clin. Lipidol. 2, 36-42 (2008).
170. Hunninghake, D. B. et al. Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia. Coron. Artery Dis. 15, 115-123 (2004).
171. Jacobson, T. A. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia. Int. J. Clin. Pract. 65, 82-101 (2011).
172. Fonseca, V., Handelsman, Y. & Staels, B. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes. Metab. 12, 384-392 (2010).
173. Bays, H. E. et al. Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J. Clin. Lipidol. 2, 426-435 (2008).
174. Davidson, M. H., Armani, A., McKenney, J. M. & Jacobson, T. A. Safety considerations with fibrate therapy. Am. J. Cardiol. 99, 3C-18C (2007).
175. Costet, P. et al. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis 212, 246-251 (2010).
176. Matteucci, E. & Giampietro, O. Statin intolerance: why and what to do-with a focus on diabetic people. Curr. Med. Chem. 20, 1397-1408 (2013).
177. Bays, H. E. et al. Icosapent ethyl, a pure EPA omega-3 fatty acid:
178. Rubenfire, M., Brook, R. D. & Rosenson, R. S. Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. Am. J. Med. 123, 892-898 (2010).
179. Bonds, D. E. et al. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia 55, 1641-1650 (2012).
180. Guyton, J. R. & Bays, H. E. Safety considerations with niacin therapy. Am. J. Cardiol. 99, 22C-31C (2007).